Ibuprofen is a household name—the go-to remedy for everything from headaches to period pain. But recent research suggests ...
"We have heard from many other readers who have also experienced a jump in blood pressure while taking a nonsteroidal ...
Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek ...
Discover why a sudden and unexpected change in your senses is a warning symptom you should never ignore, and when to see a ...
Now the Tilleys, like the nearly 500,000 people across Pennsylvania enrolled in Pennie, the state’s Affordable Care Act ...
Pfizer's BRAFTOVI + MEKTOVI Shows Sustained Long-Term Survival In Patients With Advanced Lung Cancer
Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib ...
Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in ...
Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the ...
(Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI ® (enzalutamide), in combination with leuprolide ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback